Loading data for APGE — first visit, this takes a few seconds.

알림

Apogee Therapeutics Inc. (APGE)

NasdaqGM: APGE · 실시간 가격 · USD

134.97

+0.01 (0.01%)

종가 기준: Aug 28, 2026, 3:59 PM

135.02

+0.04%

애프터마켓: 7:30 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

0.01% (1D)

매수호가	96.59
시가총액	10.22B
매출 (ttm)	n/a
순이익 (ttm)	-294.37M
	0.34
	-4.35
	n/a
	-25.79
P/B (ttm)	8.48
P/S (ttm)	n/a
실적 발표일	Nov 9, 2026

매도호가	171.87
거래량	438,760
평균 거래량 (20일)	2,745,920
시가	134.95
전일 종가	134.96
일중 범위	134.93 - 134.97
52주 범위	35.39 - 134.99
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

APGE 소개

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clin...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jul 14, 2023

직원 수 261

상장 거래소 NasdaqGM

티커 APGE

웹사이트 https://www.apogeetherapeutics.com

전체 기업 정보

재무 실적

2025년 Apogee Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -255.84M로, 40.46% 증가했습니다.

재무제표

어닝 서프라이즈

Apogee Therapeutics가 Aug 10, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS -1.08 예상치 하회 -0.12, 및 4.42% 전년 대비 성장.

다음 실적 발표

Apogee Therapeutics Inc.의 실적 발표 예정일은 Nov 9, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2주 전 · Trefis

AbbVie Defends Its Turf, But Leaves One Big Question Open

AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.

2주 전 · 24/7 Wall St.

Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield

Two healthcare giants, two very different dividend bets: one built on six decades of unbroken raises and a fortress balance sheet, the other dangling a fatter yield while racing to outrun its own bloc...

2주 전 · Motley Fool

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.

2주 전 · Motley Fool

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

The pharmaceutical company hopes that another big-time acquisition will pay off.

3주 전 · Simply Wall St.

AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed

In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and co...

2 페이지 중 1

Apogee Therapeutics Inc. (APGE)